Picture EBD Group BIO-Europe 2019 Partnering Report BEU2019 650x80px
Document › Details

Domain Therapeutics S.A.. (11/4/09). "Press Release: Domain Therapeutics Announces Successful Completion of the First Milestone in Its Research Agreement with Takeda Pharmaceutical". Strasbourg.

Organisations Organisation Domain Therapeutics S.A.
  Group Domain Therapeutics (Group)
  Organisation 2 Takeda Pharmaceutical Co., Ltd. (TSE: 4502)
  Group Takeda (Group)
Products Product drug discovery services
  Product 2 positive allosteric modulator (PAM)
Index term Index term Takeda–Domain Therapeutics: DTect-All technology, 200911 supply service existent use of DTect-All to discover GPCR-targeting drug candidates
Persons Person Neuville, Pascal (Domain Therapeutics 200812c– CEO)
  Person 2 Lloyd, Andrew (Andrew Lloyd & Associates)

Domain Therapeutics, a drug discovery company focused on G Protein-Coupled Receptors (GPCRs), announces today that it has successfully completed the first milestone in its research agreement with Takeda Pharmaceutical. This research agreement initially concerns the use of Domain's DTect-All™ technology for the discovery of novel drug candidates for GPCRs of interest to Takeda.

"Achievement of this milestone is a firm confirmation of the ability of Domain Therapeutics' unique technology to address difficult GPCRs," said Pascal Neuville, CEO of Domain Therapeutics. "We are confident that its continued use will further the goals of this on-going research program."

DTect-All™ is Domain's proprietary technology platform dedicated to identification of GPCR ligands, more specifically allosteric modulators. DTect-All™ addressees every GPCR including challenging ones such as orphan and peptidic receptors. For this milestone, Domain will receive an undisclosed success fee.

About G Protein-Coupled Receptors (GPCRs)

GPCR targets account for 40-50% of currently marketed drugs and for more than $30B in annual sales. Their potential remains tremendous, as more than 300 are still unexploited because difficult to address. To tackle these, there is a need for new technologies, for example ones able to address orphan and peptidic GPCRs. Another challenge is the identification of allosteric modulators, a new class of GPCR ligands that are considered safer than standard agonist/antagonist molecules. Domain Therapeutics' DTect-All™ technology addresses both these unmet needs and will enable the company to participate broadly in the rapidly growing GPCR drug discovery efforts.

About Domain Therapeutics S.A.

Domain Therapeutics is a biopharmaceutical company located in Strasbourg, France, dedicated to the discovery and early development of small molecules targeting G-coupled Protein Receptors (GPCRs), one of the best classes of drug targets. Domain Therapeutics uses DTect-All™, its innovative and proprietary technology platform, to identify allosteric modulators, including Silent Allosteric Modulators (SAMs) that represent a unique source of compounds that cannot be discovered by standard technologies. The platform addresses difficult GPCRs such as orphan and peptidic receptors. The company's pipeline is composed of new chemical entities, ranging from hits to preclinical candidates, and targeting hot GPCRs for leading indications such as schizophrenia, Parkinson's disease, and diabetes.

Contact for Media & Analysts

Andrew Lloyd & Associates
Neil Hunter/Andrew Lloyd
Tel: +44 1273 675 100

Record changed: 2019-06-09


Picture [LSA] – The Business Web Portal 650x89px

More documents for Domain Therapeutics (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group BIO-Europe 2019 Partnering Report BEU2019 650x80px

» top